Status and phase
Conditions
Treatments
About
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered once daily in dry eye disease (DED) patients with severe keratitis, as well as its safety and efficacy.
Full description
In this phase IV clinical trial the Month 3 visit assessments will be used to assess the efficacy (quality of vision and other parameters) and safety of IKERVIS® in DED patients with severe keratitis.
To assess the effect on the quality of vision of IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily in adult dry eye disease (DED) patients with severe keratitis over 3 months of treatment.
To assess the safety of DED patients with severe keratitis treated with IKERVIS® (1mg/mL ciclosporin) for 3 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient eligibility is determined according to the following criteria:
In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements.
The patient signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures
Male or female patient is aged 18 years or above.
DED patients with persistent severe keratitis at the Screening and
Baseline Visits defined as the following:
• CFS score of 3, 4 or 5 on the modified Oxford scale
Patient must be willing and able to undergo and return for scheduled study-related examinations.
The same eye (eligible eye) should fulfill all the above criteria.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
17 participants in 1 patient group
Loading...
Central trial contact
Elsa LLOBET-MERKLING
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal